References
- Langabeer SE. Is the BCR-ABL1 transcript type in chronic myeloid leukaemia relevant? Med Oncol. 2013;30:508.
- Branford S, Rudzki Z, Hughes TP. A novel BCR-ABL transcript (e8a2) with the insertion of an inverted sequence of ABL intron 1b in a patient with Philadelphia-positive chronic myeloid leukaemia. Br J Haematol. 2000;109:638–637.
- Demehri S, Paschka P, Schultheis B, et al. E8a2 BCR-ABL: more frequent than other atypical BCR-ABL variants? Leukemia. 2005;19:681–684.
- Cayuela JM, Rousselot P, Nicolini F, et al. Identification of a rare e8a2 BCR-ABL fusion gene in three novel chronic myeloid leukemia patients treated with imatinib. Leukemia. 2005;19:2234–2236.
- Qin YZ, Jiang B, Jiang Q, et al. Imatinib mesylate resistance in a chronic myeloid leukemia patient with a novel e8a2 BCR-ABL transcript variant. Acta Haematol. 2008;120:146–149.
- Demehri S, O’Hare T, Eide CA, et al. The function of the pleckstrin homology domain in BCR-ABL-mediated leukemogenesis. Leukemia. 2010;24:226–229.
- Huet S, Dulucq S, Chauveau A, et al. Molecular characterization and follow-up of five CML patients with new BCR-ABL1 fusion transcripts. Genes Chromosomes Cancer. 2015;54:595–605.
- Goh HG, Wang JY, Kim SH, et al. Comprehensive analysis of BCR-ABL transcript types in Korean CML patients using a newly developed multiplex RT-PCR. Transl Res. 2006;148:249–256.
- Deshpande PA, Srivastava VM, Mani S, et al. Atypical BCR-ABL1 fusion transcripts in adult B-acute lymphoblastic leukemia, including a novel fusion transcript – e8a1. Leuk Lymphoma. 2016;57:2481–2484.
- Dongen JJ, Macintyre EA, Gabert JA, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia. 1999;13:1901–1928.
- Gabert J, Beillard E, van der Velden VH, et al. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – a Europe Against Cancer program’. Leukemia. 2003;17:2318–2357.
- Verma D, Kantarjian HM, Jones D, et al. Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance. Blood. 2009;114:2232–2235.
- Hanfstein B, Lauseker M, Hehlmann R, et al. Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib. Haematologica. 2014;99:1441–1447.
- Hughes TP, Saglio G, Kantarjian HM, et al. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood. 2014;123:1353–1360.
- Langabeer SE. Standardized molecular monitoring for variant BCR-ABL1 transcripts in chronic myeloid leukemia. Arch Pathol Lab Med. 2015;139:969.